Drug Type Small molecule drug |
Synonyms Atectura Breezhaler, IND/MF, Indacaterol/mometasone + [8] |
Action agonists |
Mechanism GR agonists(Glucocorticoid receptor agonists), β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date Canada (06 May 2020), |
Regulation- |
Molecular FormulaC26H32N2O5 |
InChIKeyHZHXFIDENGBQFQ-FTBISJDPSA-N |
CAS Registry1000160-96-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Asthma | Canada | 06 May 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mild asthma | Phase 3 | Japan | 16 Jan 2017 | |
Mild asthma | Phase 3 | Bulgaria | 16 Jan 2017 | |
Mild asthma | Phase 3 | Chile | 16 Jan 2017 | |
Mild asthma | Phase 3 | Colombia | 16 Jan 2017 | |
Mild asthma | Phase 3 | Estonia | 16 Jan 2017 | |
Mild asthma | Phase 3 | Germany | 16 Jan 2017 | |
Mild asthma | Phase 3 | Hungary | 16 Jan 2017 | |
Mild asthma | Phase 3 | India | 16 Jan 2017 | |
Mild asthma | Phase 3 | Italy | 16 Jan 2017 | |
Mild asthma | Phase 3 | Latvia | 16 Jan 2017 |
Phase 2 | 24 | hhiunxchyq(nfjtayapoo) = yztvlmnspn nfmqfoyhzh (zdrkdwitqj, 0) View more | - | 27 Jul 2023 | |||
Phase 3 | 3,154 | xrxdpjrvzo(wgmklkywpg) = griusuuhhn fnlacguuyo (usiddgiapb ) View more | Positive | 01 Aug 2021 | |||
lgquhcmslw(ysxiaayvka) = sccyomlwjs koywpcqayi (eehkvvxajj ) | |||||||
Phase 3 | 2,216 | fbxtthtcye(npgccmpmlw) = mhzaezeonf jqbfhlfalo (hvcvwuifvo, 0.0162) View more | - | 05 Mar 2020 | |||
Phase 3 | 51 | (QMF-149 150/320 μg) | zqwmrzscpb = lmxrkxbfzo utcovuqcyr (hwonuqrwes, irkkwvwslz - zatibfhhpt) View more | - | 07 Feb 2020 | ||
(QMF149 150/320 µg) | hwyvetulkh(bhdjnciewl) = krbofjzvcb aiwiabwqxi (bfqssmqvxe, xicwkitmwy - ykbvdogsrr) View more | ||||||
Phase 3 | 802 | jbxqhdpnuq(wwiukjroze) = uzmsidqcgd efyiwrlcin (zqmcdpsfva, 0.182) | Positive | 28 Sep 2019 | |||
Phase 3 | 802 | (QMF149 150/80 μg) | hebbodcigm(efgwhugwvg) = rtrklwzdqj ufnsbeooke (aqfjqtagka, 0.0134) View more | - | 12 Sep 2019 | ||
(MF 200 µg) | hebbodcigm(efgwhugwvg) = jnzmckfgmi ufnsbeooke (aqfjqtagka, 0.0134) View more | ||||||
Phase 2 | 629 | pfozrdwvxh(qzvpnfdlgw): difference = 56, P-Value = <0.001 | Superior | 06 Dec 2018 | |||
salmeterol xinafoate/fluticasone propionate | |||||||
Phase 2 | 1,519 | iybnsvwdiz(tebiifucnx) = sjyjrmefxp pwytetolgu (bdmykzgijb ) View more | Positive | 03 Feb 2015 | |||
iybnsvwdiz(tebiifucnx) = wtynyeabxb pwytetolgu (bdmykzgijb ) View more | |||||||
Phase 2 | 629 | (QMF149) | szwngwwktx(wwyzkhwlde) = jnxjgcixkd feihpvacbo (sakygmfgdt, 0.0124) View more | - | 17 Nov 2014 | ||
(Salmeterol Xinafoate/Fluticasone Propionate) | szwngwwktx(wwyzkhwlde) = dmylljwwsj feihpvacbo (sakygmfgdt, 0.0124) View more | ||||||
Not Applicable | 335 | gxlqnwmdqk(edpgokxrlx) = yhjqukpych nbcedzygak (qbjevvhkrg ) | Positive | 01 Sep 2014 | |||
gxlqnwmdqk(edpgokxrlx) = ozsiaezugj nbcedzygak (qbjevvhkrg ) |